Novel Selective IDO1 Inhibitors with Isoxazolo[5,4-d]pyrimidin-4(5H)-one Scaffold

Area of Science:

• Medicinal Chemistry
• Immunology
• Pharmacology

Background:

• Indoleamine 2,3-dioxygenase 1 (IDO1) is a key enzyme in immune modulation, particularly relevant in cancer.
• Targeting IDO1 offers a promising strategy for developing novel cancer immunotherapies.

Purpose of the Study:

• To synthesize and characterize novel IDO1 inhibitors utilizing the isoxazolo[5,4-d]pyrimidin-4(5H)-one scaffold.
• To investigate structure-activity relationships (SAR) for optimizing inhibitor potency and selectivity.

Main Methods:

• A focused library of compounds was synthesized via a 6- or 7-step procedure.
• Structure-activity relationships were systematically explored through chemical modifications.
• In vitro assays were performed to determine IC50 values against human IDO1 (hIDO1), IDO2, and tryptophan dioxygenase.

Main Results:

• Discovery of best-in-class IDO1 inhibitors with IC50 values in the low micromolar range.
• Identification of key substituted aniline moieties (p-trifluoromethyl, p-cyclohexyl, p-methoxycarbonyl) crucial for potency.
• Demonstrated selectivity of the synthesized compounds for hIDO1 over IDO2 and tryptophan dioxygenase.

Conclusions:

• Successful development of IDO1-selective inhibitors based on the novel isoxazolo[5,4-d]pyrimidin-4(5H)-one scaffold.
• These compounds represent promising chemical probes for further research into small-molecule immunomodulators.
• The findings support the potential of this scaffold for advancing cancer immunotherapy.